CYCLOHEXANE COMPOUND AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME

The present invention intends to provide a novel cyclohexane compound that can form a liquid crystal composition of which response speed is improved when mixed with a nematic liquid crystal and the like and to provide a specified liquid crystal composition in which a novel cyclohexane compound is mixed. The novel cyclohexane compound is represented by the following formula (1). 5. A liquid crystal composition comprising:{'claim-ref': [{'@idref': 'CLM-00003', 'claim 3'}, {'@idref': 'CLM-00004', 'claim 4'}], 'the liquid crystal composition of mixed with at least one kind of a compound of a compound group of the formula (7) of .'}6. A liquid crystal composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'one or two or more kinds of the cyclohexane compound groups of .'}7. Use of the liquid crystal composition described in in an electrooptical application.8. An electrooptical display device comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the liquid crystal composition of encapsulated in a liquid crystal cell.'} The present invention relates to a novel cyclohexane compound and a liquid crystal composition containing the new cyclohexane, and intends to improve the response speed of a liquid crystal display.Many liquid crystal display devices that make use of the optical anisotropy (Δn) (hereinafter, referred to as “Δn” in some cases) or the dielectric constant anisotropy (Δε) (hereinafter, referred to as “Δε” in some cases), which are features of a liquid crystal compound, have been manufactured and have been used in watches, calculators, measurement instruments, instrument panels for vehicles, word processors, electronic diaries, portable telephones, printers, computers, TVs and so on. A liquid crystal compound used in liquid crystal display devices has a specific liquid crystal phase, and the phase mode thereof can be roughly divided into a nematic phase, a smectic phase and a cholesteric phase. Among these, a nematic phase is most widely ...

Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom

The present invention is concerned with Capsicum plants producing greater than about 0.4% zeaxanthin, by weight in the dried, ripe fruit pod flesh, which plants have been developed from commercially grown Capsicum cultivars by plant breeding techniques. Zeaxanthin is the dominant carotenoid in the dried ripe fruit pod flesh, when measured in non-esterified forms. Alternatively, these plants may be characterized as exhibiting a high pigmentation measured as an ASTA value and further characterized by the predominant presence of zeaxanthin. The zeaxanthin derived from these Capsicum plants can be used in applications that include nutritional supplements, foods, functional foods, cosmetics, animal feeds, aquaculture feeds, and pharmaceuticals.

Monomer for hardmask composition and hardmask composition including the monomer and method of forming patterns using the hardmask composition

A monomer for a hardmask composition is represented by the following Chemical Formula 1,

METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE

The present invention provides, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the production of formula (I). The present invention relates to a new method for producing (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide represented by Formula (I) which is a heterocyclidene acetamide derivative. Furthermore, the present invention relates to a new method for producing (R)-8-amino-1,2,3,4-tetrahydronaphthalen-2-ol represented by Formula (B) or a salt thereof, which is an intermediate useful for producing the compound represented by Formula (I).(E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide represented by Formula (I) is a transient receptor potential vanilloid 1 (TRPV1) antagonist, and is anticipated as a preventive and/or therapeutic agent for diseases involving the TRPV1 receptor (for example, pain (for example, neuropathic pain, diabetic neuralgia, postoperative pain, osteoarthrosis, rheumatoid arthritis pain, inflammatory pain, cancer pain, migraine and the like), nervous disorders, nerve damage, neurodegeneration, chronic obstructive pulmonary disease, asthma, rhinitis, inflammation of mucous membranes such as in the eyes, nervous skin disease, inflammatory skin disease, allergic disease, urinary incontinence, urge incontinence, overactive bladder, cystitis, pruritus, and the like) (Patent Literature 1).WO 2007/010383 (Patent Literature 1) discloses a method for producing the compound represented by Formula (I). In the document, the compound represented by Formula (I) is produced in steps of to shown in the following (scheme A). A compound represented by Formula (IM-k) is obtained by performing a condensation reaction using 8-amino-3,4-dihydronaphthalen-2(1H)-one (Formula (IM-3)) produced ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (I): 2. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or alkyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris alkyl;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain; and'}{'sup': '9', 'each Ris independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl.'}3. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is substituted with one hydrogen;C14 is substituted with one hydrogen;C15 is substituted with two hydrogens;{'sup': '1', 'Ris —OH;'}{'sup': '2', 'sub': '2', 'Ris —CH—OH;'}{'sup': 4a', '4b', '7', '3, 'sub': 2', '2', '2', '2', '3', '3, 'Ris hydrogen or methyl, Ris a direct bond to the carbon to which Ris attached, and Ris —CHNHor —CHN(H)C(O)(CH)CH;'}{'sup': '5', 'Ris methyl;'}{'sup': '6', 'Ris hydrogen; and'}{'sup': '7', 'Ris hydrogen.'}4. The compound of selected from:(1S,3S,4R)-4-((3aS,6S,7R,7aS)-7-(aminomethyl)-3,3a-dimethyl-3a,4,5,6,7,7a-hexahydro-1H-inden-6-yl)-3-(hydroxymethyl)-4-methylcyclohexanol; andN-(((3aR,6S,7R,7aS)-6-((1R,2S,4S)-4-hydroxy-2-(hydroxymethyl)-1-methylcyclohexyl)-3a-methyl-3a,4,5,6,7,7a-hexahydro-1H-inden-7-yl)methyl)pentanamide.6. The compound of wherein:C1, C4, C11 and C12 are each independently substituted with two hydrogens;C9 is ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (II): wherein A, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 4a', '4b, 'or Rand Rtogether form alkylidene or haloalkylidene;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl;'}optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, ...

PROCESS FOR THE PREPARATION OF 4-(8-(2-CHLOROPHENOXY)-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YL)BICYCLO[2.2.1]HEPTAN-1-OL AND NOVEL INTERMEDIATES THEREFOR

A process is provided for preparing 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates used in the process. The compound is a 11-beta hydroxysteroid dehydrogenase type I inhibitor which exhibits activity in the treatment of various metabolic diseases. 6. The process as defined in where the oxidation is carried out in the presence of sodium chlorite claim 4 , 2 claim 4 ,2 claim 4 ,6 claim 4 ,6-tetramethylpiperidine-N-oxide and sodium hypochlorite.8. The process as defined in wherein the reaction is carried out under an inert atmosphere at a temperature within the range from about 0 to about 5° C.10. The process as defined in wherein the carboxylic acid is benzoic acid and the reaction is carried out at a temperature within the range from about 105 to 110° C. This application claims priority to U.S. Provisional Application Ser. No. 62/033,695, filed Aug. 6, 2014; the entire content of which is incorporated herein reference.The invention generally relates to novel intermediates and an improved process for the preparation of 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol, a 11-beta hydroxysteroid dehydrogenase type I inhibitor which was recently in clinical trials for the treatment of type 2 diabetes, obesity, and the metabolic syndrome.The steroid hormone cortisol is a key regulator of many physiological processes. However, an excess of cortisol, as occurs in Cushing's Disease, provokes severe metabolic abnormalities including: type 2 diabetes, cardiovascular disease, obesity, and osteoporosis. Many patients with these diseases, however, do not show significant increases in plasma cortisol levels. In addition to plasma cortisol, individual tissues can regulate their glucocorticoid tone via the in situ conversion of inactive cortisone to the active hormone cortisol. Indeed, the normally high plasma concentration of cortisone provides a ready supply of precursor for conversion ...

SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS

Disclosed are 2-methylene analogs of vitamin Dand related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D, (20S)-1α-hydroxy-2-methylene-vitamin D, and (5E)-1α,25-dihydroxy-2-methylene-vitamin D, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders. 2. The compound of claim 1 , wherein Xand Xare t-butyldimethylsilyl.3. The compound of claim 1 , wherein Xand Xare hydrogen.6. A pharmaceutical composition containing an effective amount of the compound of and a pharmaceutically acceptable excipient.7. A method of treating or preventing a bone disease or disorder in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .8. A method for increasing bone strength in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .9. A method of treating or preventing a skin disease claim 1 , disorder claim 1 , or condition in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .10. A method of treating or preventing a cell proliferative disease or disorder in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .11. A method of treating or preventing obesity claim 1 , inhibiting adipocyte differentiation claim 1 , inhibiting SCD-1 gene transcription claim 1 , and/or reducing body fat in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .12. A method of treating secondary hyperparathyroidism of renal osteodystrophy in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount ...

TRANS-CYCLOHEPTENES AND HETERO-TRANS-CYCLOHEPTENES FOR BIOORTHOGONAL COUPLING

A substituted trans-cycloheptene according to formula (I); wherein: a) Z and L are each selected from the group consisting of SiR, CH, CHOH, and CHR; Ris phenyl or CH; Ris phenyl, CH, (CH)CN, or (CH)OH, wherein n is an integer from 1 to 5; Rand Rare each individually selected from the group consisting of H, OH, and CH; and Z and L are not both SiRR; or b) Z is BocN, L is CH, Ris H, and Ris H; or c) Z is C=0, L is CH, Ris H, and Ris H. 2. The substituted trans-cycloheptene according to claim 1 , wherein Z claim 1 , L claim 1 , R claim 1 , and Rare according to any one of combinations a) through l):{'sub': '2', 'sup': a', 'b, 'a) Z is CHOH, L is CH, Ris H, and Ris H;'}{'sub': 2', '2, 'sup': a', 'b, 'b) Z is CHCHOH, L is CH, Ris H, and Ris H;'}{'sub': 2', '2, 'sup': a', 'b, 'c) Z is CH, L is CH, and Ris OH, and Ris H;'}{'sub': '2', 'sup': a', 'b, 'd) Z is CH, L, is CHOH, Ris OH, and Ris H;'}{'sub': '2', 'sup': a', 'b, 'e) Z is BocN, L, is CH, Ris H, and Ris H;'}{'sub': '2', 'sup': a', 'b, 'f) Z is C═O, L is CH, Ris H, and Ris H;'}{'sup': 1', '2', 'a', 'b', '1', '2, 'sub': 2', '3', '2', '3', '2', '4, 'g) Z is SiRR, L is CH, Ris H, Ris H, Ris CH, and Ris either (CH)CN or (CH)OH;'}{'sub': 3', '2', '3', '2', '3', '3, 'sup': a', 'b, 'h) Z is SiCH(CH)OH, L is CH, Ris CH, and Ris CH;'}{'sub': 2', '2, 'sup': a', 'b, 'i) Z is SiPh, L is CH, Ris H, and Ris H;'}{'sub': 3', '2', '2, 'sup': a', 'b, 'j) Z is Si(CH), L is CH, Ris OH, and Ris H;'}{'sub': 2', '2, 'sup': a', 'b, 'k) is CH, L is SiPh, Ris H, and Ris H;'}{'sub': 2', '3', '2', '4, 'sup': a', 'b, 'l) Z is CH, L is SiCH(CH)OH, Ris H, and Ris H.'}3. An adduct of the substituted trans-cycloheptene according to with a molecule selected from the group consisting of tetrazines claim 1 , ketenes claim 1 , conjugated dienes claim 1 , and 1 claim 1 ,3-dipoles.4. The adduct according to claim 3 , wherein the molecule is a tetrazine.5. The adduct according to claim 3 , wherein the molecule is a ketene.6. The adduct according to claim ...

Phenylcyclohexanol Derivatives As Wax Modifiers And Gelators

A compound of the formula 3. (canceled)4. (canceled)5. (canceled)11. The composition of claim 10 , wherein the carrier comprises a member of the group consisting of wax claim 10 , oil claim 10 , solvent claim 10 , water claim 10 , organic liquid claim 10 , inorganic liquid claim 10 , and combinations thereof.12. (canceled)13. (canceled)15. The phase change ink of claim 14 , wherein the carrier comprises at least one wax.16. The phase change ink of claim 14 , wherein the carrier comprises at least one wax having a melting point of 120° C. or higher.17. (canceled)18. (canceled)20. (canceled) In general, phase change inks (sometimes referred to as solid inks or “hot melt inks”) are in the solid phase at ambient temperature, but exist in the liquid phase at the elevated operating temperature of an ink jet printing device. At the jet operating temperature, droplets of liquid ink are ejected from the printing device and, when the ink droplets contact the surface of the recording substrate, either directly or via an intermediate heated transfer belt or drum, they quickly solidify to form a predetermined pattern of solidified ink drops. Phase change inks have also been used in other printing technologies, such as gravure printing.Phase change inks for color printing typically comprise a phase change ink carrier composition which is combined with a phase change ink compatible colorant. In a specific embodiment, a series of colored phase change inks can be formed by combining ink carrier compositions with compatible subtractive primary colorants. The subtractive primary colored phase change inks can comprise four component dyes, namely, cyan, magenta, yellow and black, although the inks are not limited to these four colors. These subtractive primary colored inks can be formed by using a single dye or a mixture of dyes. For example, magenta can be obtained by using a mixture of Solvent Red Dyes or a composite black can be obtained by mixing several dyes. U.S. Pat. No. 4,889, ...

Use of dicyclohexylmethanol derivatives having antimicrobial properties

The present invention relates to the use of at least one dicyclohexylmethanol derivative of the formula (I) as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific dicyclohexylmethanol derivatives and to a process for the preparation thereof.

CYCLIC COMPOUND CONTAINING FUNCTIONAL GROUP OR CONTAINING NO FUNCTIONAL GROUP, AND METHOD FOR PRODUCING SAME

This invention selectively synthesizes a cycloparaphenylene compound having 10, 11, or 13 benzene rings. The invention also synthesizes a cycloparaphenylene compound in which a functional group is introduced into a desired portion. By reacting specific raw materials using a specific reaction, a cyclic compound having 10, 11, or 13 bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof can be selectively obtained as a pure substance. Further, by a method comprising the step of reacting a specific organic compound containing no functional group with a specific organic compound containing a functional group, it is possible to obtain a cyclic compound containing a functional group in which one or more bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof of a compound having 10 or more bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof is substituted with a substituted 1,4-phenylene group. 2. The cyclic compound containing a functional group according to claim 1 , wherein the cyclic compound has 1 group represented by General Formula (2) claim 1 , and 9 or more bivalent aromatic hydrocarbon groups claim 1 , bivalent heterocyclic groups claim 1 , or derivative groups thereof.3. The cyclic compound containing a functional group according to claim 1 , wherein R is a halogen atom.6. The method according to claim 5 , wherein the compound containing no functional group is a compound represented by General Formula (VII-1):{'br': None, 'sup': '2', 'Y—R—Y'}{'sup': '2', 'claim-text': {'br': None, 'sup': '3', 'Y—R—Y'}, 'wherein Ris a bivalent group containing 1 to 3 structural units represented by General Formula (1) and 2 or more bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof; and Y is as defined above, and the compound containing a functional group is a compound represented by General Formula (VII-2 ...

TOBACCO-DERIVED COMPONENTS AND MATERIALS

The invention provides a method of extracting and isolating certain compounds from tobacco. The resulting isolate can include more than 90% by weight of a given compound and can be used as a flavor component for tobacco material used in smoking articles and smokeless tobacco compositions. Exemplary compounds that may be present in the isolate according to the invention include, but are not limited to, solanone, neophytadiene, megastigmatrienone, β-damascenone, norsolanadione, cis-abienol, α-cembratrienediol, β-cembratrienediol, sucrose esters, and lutein. 1Nicotiana. A method of extracting and isolating compounds from plants of the species , comprising:{'i': 'Nicotiana', 'receiving a plant material of the species;'}contacting the plant material with a solvent for a time and under conditions sufficient to extract one or more desired compounds from the plant material into the solvent;separating the solvent containing the one or more desired compounds from the extracted plant material; andpurifying the solvent containing the one or more desired compounds to provide an isolate comprising at least about 75 percent by weight of the one or more desired compounds, the one or more desired compounds being selected from the group consisting of solanone, neophytadiene, megastigmatrienone, β-damascenone, norsolanadione, cis-abienol, α-cembratrienediol, β-cembratrienediol, sucrose esters, lutein, degradation products thereof, and mixtures thereof.2Nicotiana. The method of claim 1 , wherein the plant material of the species is in a form selected from the group consisting of whole leaf claim 1 , laminae claim 1 , cut filler claim 1 , volume expanded claim 1 , stems claim 1 , cut-rolled stems claim 1 , cut-puffed stems claim 1 , reconstituted tobacco claim 1 , and particulate.3Nicotiana. The method of claim 1 , wherein the plant material of the species is provided in green form.4Nicotiana. The method of claim 1 , wherein the plant material of the species is provided in cured form.5. ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (II): 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;'}{'sup': '11', 'Ris optionally substituted heteroaryl; and'}{'sup': '12', 'Ris optionally substituted heterocyclyl.'}4. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each alkyl;'}{'sup': '5', 'Ris a direct bond to the carbon at C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup ...

Method for Producing Lutein from Tobacco

A method for producing lutein from one or more plants of genus is provided. The lutein can be derived inter alia from species biomass. A method such as is described in various embodiments herein also provides articles and compositions that include lutein produced from one or more plants of genus

Novel Biphenyl Derivative Compound and Use Thereof

The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis. 2. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the Cto Calkoxy group is any one selected from the group consisting of methoxy claim 1 , ethoxy and propoxy groups.3. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein Rto Rare each independently hydroxy or methoxy.4. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to claim 3 , wherein each of R claim 3 , R claim 3 , Rand Ris independently hydroxy or methoxy and wherein at least two of R claim 3 , R claim 3 , Rand Rare methoxy groups.5. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein L is —(C—C)— claim 1 , and each of R claim 1 , R claim 1 , Rand Ris methoxy.7. A pharmaceutical composition for treating or preventing cancer claim 1 , the pharmaceutical composition containing claim 1 , as an active ingredient claim 1 , the biphenyl derivative compound or pharmaceutically acceptable salt thereof according to .8. The pharmaceutical composition of claim 7 , wherein the cancer is cancer selected from the group consisting of breast cancer claim 7 , lung cancer claim 7 , melanoma claim 7 , prostate cancer claim 7 , colorectal cancer claim 7 , bladder cancer claim 7 , bone cancer claim 7 , blood cancer claim 7 , thyroid cancer claim 7 , parathyroid cancer claim 7 , bone marrow cancer claim 7 , rectal cancer claim 7 , throat cancer claim 7 , ...

Process for Preparing Xanthophyll Crystal

Disclosed a process for preparing a xanthophyll crystal, comprising: dissolving the plant extract containing a xanthophyll ester in n-hexane, then filtering the mixture; adding acetone to the filtrate, filtering and collecting a filter cake; mixing the filter cake with soybean oil and ethanol uniformly; saponifying the mixed solution with alkaline aqueous solution; then adding an acidic solution thereto until the mixed solution becomes acidic, concentrating under reduced pressure to obtain a pasty substance; adding n-hexane to the pasty saponified product, standing still and then conducting a solid-liquid separation; washing the resulting solid substance with deionized water; adding a mixed solvent to the washed solid substance, dissolving it with stirring; and then adding n-hexane thereto and standing still to recrystallize. According to the application, organic solvents are used to treat the plant extract and remove non-xanthophyll ester compounds in order to improve the efficiency of the saponification reaction; the saponified solution is concentrated under acidic condition at reduced pressure, then extracted with an organic solvent for saving water; purifying a xanthophyll crystal with a mixed solvent in order to significantly increase the purity of a xanthophyll crystal and proportion of trans-xanthophyll. 1. A process for preparing xanthophyll crystal , comprising the following steps:a) dissolving a plant extract containing a xanthophyll ester in n-hexane, then filtering the mixture;b) adding acetone to the filtrate, standing still, then filtering and collecting a filter cake;c) dissolving the filter cake with soybean oil and ethanol in order to obtain a mixed solution;d) saponifying the mixed solution with an alkaline aqueous solution;e) adding an acidic solution to the saponified solution until the mixed solution becomes acidic, and maintaining the temperature between 40-60° C. during the process of adding the acidic solution;f) recovering the solvent and ...

CALCIPOTRIOL MONOHYDRATE NANOCRYSTALS

Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions. 1. A suspension of calcipotriol monohydrate in the form of nanocrystals of a particle size distribution in the range of 200-600 nm as determined by dynamic light scattering , the suspension further comprising an aqueous phase including a non-ionic , polymeric surfactant in an amount sufficient to prevent formation of aggregates and/or crystal growth of the calcipotriol monohydrate nanocrystals.2. The suspension according to claim 1 , wherein the surfactant is selected from the group consisting of poloxamer or polysorbate surfactants claim 1 , and polyoxyethylene C-24 alkyl ether.3. The suspension according to claim 2 , wherein the poloxamer is selected from the group consisting of poloxamer 124 claim 2 , poloxamer 188 claim 2 , poloxamer 237 claim 2 , poloxamer 338 and poloxamer 407.4. The suspension according to claim 3 , wherein the surfactant is poloxamer 188.5. The suspension according to claim 2 , wherein the polysorbate is selected from the group consisting of polysorbate 20 claim 2 , polysorbate 40 claim 2 , polysorbate 60 claim 2 , polysorbate 61 claim 2 , polysorbate 80 and polysorbate 81.6. The suspension according to claim 2 , wherein the polyoxyethylene C24 alkyl ether is cetomacrogol 1000.7. The suspension according to claim 2 , wherein the amount of surfactant in said aqueous phase is in the range of from about 0.6% to about 1.2% by weight of the suspension.8. The suspension according to claim 1 , wherein the calcipotriol monohydrate nanocrystals have a mean particle size of 200-350 nm claim 1 , 350-400 nm or 400-500 nm as determined by dynamic light scattering.9. A process for preparing a suspension of calcipotriol monohydrate nanocrystals of a particle size distribution in the range of 200-600 nm as determined by dynamic light scattering claim 1 , ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (II): 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;'}{'sup': '11', 'Ris optionally substituted heteroaryl; and'}{'sup': '12', 'Ris optionally substituted heterocyclyl.'}4. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each alkyl;'}{'sup': '5', 'Ris a direct bond to the carbon at C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup ...

SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2-METHYLENE ANALOGS OF CALCITRIOL AND RELATED COMPOUNDS

Disclosed are 2-methylene analogs of vitamin Dand related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D, (20S)-1α-hydroxy-2-methylene-vitamin D, and (5E)-1α,25-dihydroxy-2-methylene-vitamin D, their biological activities, and various pharmaceutical uses for these compounds including methods of treating and/or preventing bone diseases and disorders. 2. The compound of claim 1 , wherein Xand Xare t-butyldimethylsilyl.3. The compound of claim 1 , wherein Xand Xare hydrogen.6. A pharmaceutical composition containing an effective amount of the compound of and a pharmaceutically acceptable excipient.7. A method of treating or preventing a bone disease or disorder in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .8. (canceled)9. A method of treating or preventing a skin disease claim 1 , disorder claim 1 , or condition in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .10. A method of treating or preventing a cell proliferative disease or disorder in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .11. A method of treating or preventing obesity claim 1 , inhibiting adipocyte differentiation claim 1 , inhibiting SCD-1 gene transcription claim 1 , and/or reducing body fat in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .12. A method of treating secondary hyperparathyroidism of renal osteodystrophy in a patient in need thereof claim 1 , the method comprising administering to the patient an effective amount of the compound of .15. A pharmaceutical composition containing an effective amount of the compound of and a pharmaceutically acceptable excipient.16. A ...

CYCLOPROPANE DERIVATIVES IN FLAVOR AND FRAGRANCE COMPOSITIONS

The present invention relates to novel cyclopropane derivatives represented by Formula I: 3. The composition of claim 2 , wherein the compound is selected from the group consisting of:1-heptyl-cyclopropanol;1-(2,6-dimethyl-heptyl)-cyclopropanol;1-(2-methyl-heptyl)-cyclopropanol;1-(6-methyl-heptyl)-cyclopropanol;1-hept-5 -enyl-cyclopropanol;1-(2,6-dimethyl-hept-5-enyl)-cyclopropanol;1-2-methyl-hept-5 -enyl-cyclopropanol;1-(6-methyl-hept-5-enyl)-cyclopropanol;2′-isobutyl-bicyclopropyl-1-ol;2′-isobutyl-bicyclopropyl-1-yl acetate;2-(2′-isobutyl-bicyclopropyl-1-yloxy)-tetrahydro-furan;2′-(2-methyl-propenyl)-bicyclopropyl-1-ol;2′-(2-Methyl-propenyl)-bicyclopropyl-1-yl acetate;2-[2′-(2-methyl-propenyl)-bicyclopropyl-1-yloxy]-tetrahydro-furan;2′-Isobutyl-3′-methyl-bicyclopropyl-1-ol;2′-Isobutyl-3′-methyl-bicyclopropyl-1-yl acetate;2-(2′-Isobutyl-3′-methyl-bicyclopropyl-1-yloxy)-tetrahydro-furan;3-Methyl-2′-(2-methyl-propenyl)-bicyclopropyl-1-ol;3-Methyl-2′-(2-methyl-propenyl)-bicyclopropyl-1-yl acetate;2-[3-Methyl-2′-(2-methyl-propenyl)-bicyclopropyl-1-yloxy]-tetrahydro-furan;3-Isobutyl-2′,2′-dimethyl-bicyclopropyl-1-ol;3-Isobutyl-2′,2′-dimethyl-bicyclopropyl-1-yl acetate;2-(3-Isobutyl-2′,2′-dimethyl-bicyclopropyl-1-yloxy)-tetrahydro-furan;2′,2′-Dimethyl-3′-(2-methyl-propenyl)-bicyclopropyl-1-ol;2′,2′-Dimethyl-3′-(2-methyl-propenyl)-bicyclopropyl-1-yl acetate; and2[2′,2′-Dimethyl-3′-(2-methyl-propenyl)-bicyclopropyl-1-yloxy]-tetrahydro-furan.4. The composition of claim 1 , wherein the composition is the flavor composition further comprising a material selected from the group consisting of a foodstuff claim 1 , a chewing gum claim 1 , a dental product claim 1 , an oral hygiene product and a medicinal product.5. The composition of claim 4 , wherein the olfactory acceptable amount is greater than about 0.1 parts per billion by weight of the composition.6. The composition of claim 4 , wherein the olfactory acceptable amount is from about 1 part per billion to about 500 parts ...

PROCEDURE FOR CRYSTALLIZATION OF (22E)-(24R)-2-METHYLENE-22-DEHYDRO-1A,24-25-TRIHYDROXY-19-NOR-VITAMIN D3

Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Dto obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Din a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Dto form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Dfrom the solution. 2. A crystalline form of (22E)-(24R)-2-methylene-22-dehydro-1α ,24 ,25-trihydroxy-19-nor-vitamin Dhaving molecular packing arrangement defined by space group P2and unit cell dimensions: a=16.3058(9) Å; b=10.0461(6) Å; c=26.0527(15) Å; α=90°; β=109.001(3)°; and y=90°.3. A three dimensional structure for (22E)-(24R)-2-methylene-22-dehydro-1α claim 2 ,24 claim 2 ,25-trihydroxy-19-nor-vitamin Das defined by the molecular packing arrangement set forth in .4. A method of purifying (22E)-(24R)-2-methylene-22-dehydro-1α claim 2 ,24 claim 2 ,25-trihydroxy-19-nor-vitamin D claim 2 , comprising the steps of:{'sub': 3', '3, '(a) dissolving (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Din a volume of ethyl acetate as solvent to prepare a solution of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D;'}{'sub': 3', '3, '(b) adding a volume of hexane dropwise to the solution, preferably to reach a saturation point, to form a solution of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Din a mixture of ethyl acetate and hexane as solvent wherein crystals of (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Dform and precipitate from the solution; and'}{'sub': '3', '(c) separating the (22E)-(24R)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin Dcrystals from the solution.'}5. The method ...

VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST

The present invention relates to compounds of pharmaceutical interest. More particularly, it relates to compounds of formula (I), to processes for obtaining thereof, to the intermediates of their synthesis and processes for obtaining the latter. The compounds of formula (I) have a certain affinity with the vitamin D receptor, they are active in a similar order to 1,25α-dihydroxyvitamin D(1,25D), with the advantage of producing less or no hypercalcemia. 2. The compound of formula (I) according to claim 1 , wherein each of Rand Ris independently selected from hydrogen claim 1 , (C-C)alkyl and (CC)hydroxyalkyl and Ris selected from (C-C)alkyl and (CC)hydroxyalkyl.3. The compound of formula (I) according to claim 2 , wherein Ris (C-C)alkyl and Ris (C-C)hydroxyalkyl.4. The compound of formula (I) according to claim 1 , wherein Ris hydrogen claim 1 , and wherein R claim 1 , Rand Rare hydrogen.5. (canceled)7. The compound of formula (Ia) claim 6 , according to claim 6 , wherein Ris (CC)alkyl claim 6 , Ris (C-C)hydroxyalkyl and Ris hydrogen.8. The compound of formula (Ia) claim 6 , according to claim 6 , wherein Ris (CC)alkyl claim 6 , Ris (C-C)hydroxyalkyl and Ris (C-C)hydroxyalkyl.9. The compound of formula (Ia) claim 6 , according to claim 6 , wherein Ris hydrogen claim 6 , Ris (C-C)hydroxyalkyl and Ris (C-C)hydroxyalkyl.10. The compound of formula (I) claim 1 , according to wherein at least one of R claim 1 , Rand Ris a branched (CC)hydroxyalkyl.11. The compound of formula (I) according to claim 1 , wherein Xand Xare methylene.12. The compound of formula (I) according to claim 1 , characterised in that it comprises isotopic labelling.13. The compound of formula (I) according to claim 12 , wherein the isotopic labelling is selected from C claim 12 , C claim 12 , C claim 12 , H and H.14. (canceled)15. The compound of formula (I) according to claim 1 , selected from the group consisting of:(1R,3S,Z)-5-((E)-3-(3-(6-hydroxy-6-methylheptyl)phenyl)pent-2-enyliden)-4-met ...

BICYCLIC ALKYL COMPOUNDS AND SYNTHESIS

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing a substituted bicyclo[1.1.1]pentane using a Group VII or Group IX transition metal compound. 2. The method of claim 1 , wherein method uses a Group VII transition metal compound.3. The method of claim 2 , wherein the Group VII transition metal compound is a cobalt-based transition metal compound.4. The method of claim 3 , wherein the cobalt compound is a Co(II) compound.5. The method of claim 3 , wherein the cobalt compound is a Co(III) compound.6. The method of claim 1 , wherein method uses a Group IX transition metal compound.7. The method of claim 6 , wherein the Group IX transition metal compound is a manganese-based transition metal compound.8. The method of claim 7 , wherein the manganese compound is a Mn(II) compound.9. The method of claim 7 , wherein the manganese compound is a Mn(III) compound.11. The method of claim 10 , wherein the transition metal compound is Mn(dmp).12. The method of any one of - claim 10 , wherein the hydride source is a metal-based hydride source.13. The method of claim 12 , wherein the metal-based hydride source is an alkali metal-based hydride source.14. The method of claim 13 , wherein the alkali metal-based hydride source is NaBH.15. The method of any one of - claim 13 , wherein the hydride source is a non-metal-based hydride source.16. The method of claim 15 , wherein the non-metal-based hydride source is a silane.17. The method of claim 16 , wherein the silane is PhSiH.18. The method of any one of - claim 16 , wherein the reagent capable of contributing all or a part of a substituent group has the structure LG-R claim 16 , wherein Rattaches to a carbon of [1.1.1]propellane and LGis a leaving group.19. The method of claim 18 , wherein the LG' is an optionally substituted sulfonyl claim 18 , an optionally substituted phosphonate claim 18 , an alkali metal or a transition metal.20. The method of claim 19 , wherein the optionally substituted ...

USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS

The invention relates to the use of substituted 1-(arylethynyl)-, 1-(heteroarylethynyl)-, 1-(heterocyclylethynyl)- and 1-(cycloalkenylethynyl)bicycloalkanols or salts thereof 4. A treatment for plants claim 1 , comprising applying a nontoxic amount claim 1 , effective for increasing the resistance of plants to abiotic stress factors claim 1 , one or more of the compounds of the formula (I) and/or a respective salt thereof as claimed in .5. The treatment as claimed in claim 4 , wherein the abiotic stress conditions are one or more conditions selected from the group consisting of aridity claim 4 , cold stress claim 4 , heat stress claim 4 , drought stress claim 4 , osmotic stress claim 4 , waterlogging claim 4 , elevated soil salinity claim 4 , elevated exposure to minerals claim 4 , ozone conditions claim 4 , strong light conditions claim 4 , limited availability of nitrogen nutrients and limited availability of phosphorus nutrients.6. A compound of formula (I) and/or a respective salt thereof as claimed in in spray application to one or more plants and/or parts of plants in combinations with one or more active compounds selected from the group of the insecticides claim 1 , attractants claim 1 , acaricides claim 1 , fungicides claim 1 , nematicides claim 1 , herbicides claim 1 , growth regulators claim 1 , safeners claim 1 , substances which affect plant maturity and bactericides.7. A compound of formula (I) and/or a respective salt as claimed in in spray application to one or more plants and/or parts of plants in combination with one or more fertilizers.8. A compound of formula (I) and/or a respective salt as claimed in for application to one or more genetically modified cultivars claim 1 , seed thereof claim 1 , and/or to one or more cultivated areas on which cultivars grow.9. A spray solution comprising one or more of the compounds of formula (I) and/or respective salt thereof as claimed in capable of being used for enhancing resistance of one or more plants to ...

HYDROGENATION METHOD FOR PREPARING HYDROGENATED BISPHENOL-A HAVING A HIGHER TRANS/TRANS ISOMER RATIO

A hydrogenation method for preparing HBPA includes placing a BPA reaction liquid into a hydrogenation vessel with a hollow-shaft stirrer installed inside; starting the hollow-shaft stirrer to stir the BPA reaction liquid and simultaneously allowing hydrogen gas evenly distributed over and contact well with the BPA reaction liquid; in the presence of a single-metallic Ru/Al2O3 hydrogenation catalyst to proceed with a catalytic hydrogenation at low temperature and low pressure to produce HBPA, the HBPA has a yield of 99.7% or more, and particularly having a trans/trans isomer ratio above 63%. 1. A hydrogenation method for preparing HBPA having a higher trans/trans isomers ratio from BPA , comprising the steps of:a) placing a BPA reaction liquid containing 5-60 wt % of BPA reactant, based on the total weight of the BPA reaction liquid, into a hydrogenation vessel provided therein with a hollow-shaft stirrer capable of extracting hydrogen gas and exhausting hydrogen gas into the BPA reaction liquid as well as stirring the BPA reaction liquid;b) adding a single-metallic Ru/Al2O3 hydrogenation catalyst in an amount of 0.02-15.0 wt % based on the weight of BPA reactant;c) maintaining constant pressure after introducing a hydrogen gas with a pressure of 40-70 bar;d) starting the hollow-shaft stirrer to stir the BPA reaction liquid, then raising the temperature to 120 to 180° C., and undergoing a catalytic hydrogenation for 10 to 20 hours; ande) after completion of the catalytic hydrogenation reaction, cooling the reaction liquid to the room temperature, filtering out the catalyst and optionally further removing the solvent to obtain a produced HBPA having a yield of 99.7% or more as well as having a trans/trans isomers ratio of above 63%.2. The hydrogenation method as defined in claim 1 , wherein at step d) the BPA reaction liquid before raising the temperature to 120 to 180° C. is in advance stirred for 10 minutes under holding the pressure of step c) and at room ...

PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS

There is described a method of preparing a compound of formula I, and optical isomers thereof; in which Ris hydrogen or a protecting group; said method comprising oxidising verbenone and optical isomers thereof. 4. The method according to in which Ris hydrogen and the method includes a step of protection of (+)-4-oxomyrtenol.5. A method of preparing a 9-(hydroxymethyl)-6 claim 1 ,6-dimethyl-3-(2-methyloctan-2-yl)-6a claim 1 ,7 claim 1 ,10 claim 1 ,10a-tetrahydrobenzo [c]chromen-1-ol cannabinoid which comprises reacting a compound of formula I in which Ris hydrogen claim 1 , with 5-(1 claim 1 ,1-dimethylheptyl)resorcinol.6. A method of preparing a 3-subtituted cannabinoid compounds which comprises reacting a compound of formula I with 5-substituted resorcinol.7. A method according to which comprises reacting a compound of formula I with 5-alkyl resorcinol.9. The method according to wherein (+)-4-oxomyrtenol is reacted with 5-(1 claim 8 ,1-dimethylheptyl)resorcinol to produce dexanabinol.10. The method according to wherein the cannabinoid is dexanabinol claim 8 , said method comprising the steps of:(i) oxidising (R)-verbenone to produce (+)-4-oxomyrtenol or protected (+)-4-oxomyrtenol;(ii) optionally protecting the hydroxy group of (+)-4-oxomyrtenol;(iii) reacting the (+)-4-oxomyrtenol, or a protected derivative thereof, with 5-(1,1-dimethylheptyl)resorcinol to produce dexanabinol, or a protected derivative thereof; and(iv) optionally deprotecting the protected derivative of dexanabinol.11. The method according to wherein (−)-4-oxomyrtenol is reacted with 5-(1 claim 8 ,1-dimethylheptyl)resorcinol to produce HU-210.12. The method according to wherein the cannabinoid is HU-210 claim 8 , said method comprising the steps of:(i) oxidising (S)-verbenone to produce (−)-4-oxomyrtenol or protected (−)-4-oxomyrtenol;(ii) optionally protecting the hydroxy group of (−)-4-oxomyrtenol;(iii) reacting the (−)-4-oxomyrtenol, or a protected derivative thereof, with 5-(1,1- ...

SHIP1 MODULATORS AND METHODS RELATED THERETO

Compounds of formula (II): 3. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each independently hydrogen, alkyl, alkenyl or alkynyl;'}{'sup': 4a', '4b', '7, 'or Ris hydrogen, alkyl, alkenyl or alkynyl and Ris a direct bond to the carbon to which Ris attached;'}{'sup': 5', '5, 'Ris alkyl or Ris a direct bond to the carbon at C14;'}{'sup': 6', '8', '9', '8', '9, 'sub': '2', 'Ris hydrogen, —R—ORor —R—N(R);'}{'sup': 7', '8', '9', '8', '9', '7', '4b', '7, 'sub': '2', 'Ris hydrogen, —R—OR, —R—N(R), or a direct bond to C15, provided that when Ris a direct bond to C15, Ris not a direct bond to the carbon to which Ris attached;'}{'sup': '8', 'each Ris independently a direct bond or a straight or branched alkylene chain;'}{'sup': '9', 'each Ris hydrogen, alkyl, optionally substituted aryl and optionally substituted aralkyl;'}{'sup': '9a', 'each Ris hydrogen, alkyl, optionally substituted aryl, optionally substituted aralkyl; optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;'}{'sup': '11', 'Ris optionally substituted heteroaryl; and'}{'sup': '12', 'Ris optionally substituted heterocyclyl.'}4. The compound of wherein:{'sup': 1', '8', '9, 'Ris —R—OR;'}{'sup': 2', '8', '9, 'Ris —R—OR;'}{'sup': 3', '8', '9', '11', '8', '9', '12', '8', '9', '9a', '8', '9', '9a', '8', '9', '9a, 'sub': 2', '2', '2, 'Ris —R—N(R)C(O)R, —R—N(R)—R, —R—N(R)C(═NCN)N(R), —R—N(R)C(O)N(R)or —R—N(R)C(S)N(R);'}{'sup': 4a', '4b, 'Rand Rare each alkyl;'}{'sup': '5', 'Ris a direct bond to the carbon at C14;'}{'sup': '6', 'Ris hydrogen;'}{'sup': '7', 'Ris hydrogen;'}{'sup ...

Method for Synthesising Cyclohexenones and the Use of Same in the Perfume Industry

The present invention concerns a method for synthesising cyclohexenone and cyclohexenol compounds having specific fragrances and remanence properties, said method consisting in condensing a ketone on an α-methylene-aldehyde in order to obtain, by means of a domino reaction, compounds of formula (I).

Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase

The present invention relates to compounds which are useful in inhibiting the hepatitis C virus NS3 helicase. These compounds are useful in pharmaceutical compositions and method for treating and preventing HCV infection.

antioxidants

Die vorliegende Erfindung betrifft die Verwendung von Verbindungen der Formel I X-Ar-Y, wobei X und Y jeweils unabhängig voneinander ausgewählt sind aus den Resten H, C<SUB>1-8</SUB>-Alkyl und den Resten gemäß den Formeln Ia, Ib oder Ic, $F1 mit in der Beschreibung definierten sonstigen Resten, als Antioxidans, entsprechende neue Verbindungen und Zubereitungen sowie entsprechende Herstellverfahren für Verbindungen und Zubereitungen. The present invention relates to the use of compounds of the formula I X-Ar-Y, where X and Y are each independently selected from the radicals H, C <SUB> 1-8 </SUB> alkyl and the radicals according to the formulas Ia, Ib or Ic, $ F1 with other radicals defined in the description, as an antioxidant, corresponding new compounds and preparations and corresponding production processes for compounds and preparations.

对氯苯胺的合成方法

提供一种对氯苯胺的合成方法，包括：以碳包覆镍纳米复合材料为催化剂，以氢气为氢源，催化对氯硝基苯制备对氯苯胺；其中，所述碳包覆镍纳米复合材料包括碳包覆镍纳米颗粒，其中所述碳包覆镍纳米颗粒由镍纳米颗粒内核和包裹在所述镍纳米颗粒表面的石墨化碳层外壳组成，并且所述石墨烯碳层外壳具有至少一个介孔分布峰。本发明利用碳包覆镍纳米复合材料作为催化剂催化对氯硝基苯加氢制备对氯苯胺的过程中无需使用脱氯抑制剂，反应选择性高，反应条件温和，产物与催化剂分离较为简便。

Microencapsulated catalyst methods of preparation and method of use thereof

A microencapsulated catalyst is prepared by dissolving or dispersing a catalyst in a first phase (for example an organic phase), dispersing the first phase in a second, continuous phase (for example an aqueous phase) to form an emulsion, reacting one or more microcapsule wall-forming materials at the interface between the dispersed first phase and the continuous second phase to form a microcapsule polymer shell encapsulating the dispersed first phase core and optionally recovering the microcapsules from the continuous phase. The catalyst is preferably a transition metal catalyst and the encapsulated catalyst may be used for conventional catalysed reactions. The encapsulated catalyst may recovered from the reaction medium and re-cycled.

Enediyne derivatives

Novel C 3 -substituted cyclodeca-1,5-diynes can be prepared through novel synthetic procedures using starting (E)-C 3 -substituted-4-(aryl- or heteroarylmethylidene)cyclodeca-1,5-diynes reagents. Both the C 3 -substituted cyclodeca-1,5-diyn-3-enes and the starting reagents have improved thermal stability compared to unsubstituted counterparts.

Transition metal catalysts for hydrogenation and hydrosilylation

Phosphoranimide-metal catalysts and their role in hydrogenation and hydrosilylation are disclosed. The catalysts comprise first row transition metals such as nickel, cobalt or iron. The catalysts have a metal to anionic phosphoranimide ratio of 1:1. This disclosure presents a process for catalytic hydrogenation and hydrosilylation of a range of unsaturated organic compounds under lower temperature and pressure conditions than conditions associated with industrial hydrogenation and hydrosilylation.

一种醇类化合物的合成方法

本发明提供一种醇类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化醛类化合物进行加氢还原反应；其中，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氧的石墨化碳层，所述内核为镍纳米颗粒，所述纳米复合材料的酸洗损失率≤60％。该方法采用含核壳结构的碳包覆镍的纳米复合材料为催化剂，产生了良好的催化效果，并有利于在更苛刻的条件下发挥作用，用于醛类化合物加氢还原合成醇类化合物，具有优异的活性、选择性及安全性。

Novel Tertiary Alcohol Compounds Having an Alicyclic Structure

본 발명은 바람직하게는 300 nm 이하의 파장, 특히 바람직하게는 ArF 엑시머 레이저광을 광원으로 한 포토리소그래피에 있어서, 투명성과 기판과의 친화성이 우수한 포토레지스트 재료 제조용 단량체로서 유용한 신규 3차 알콜 화합물을 제공한다. The present invention preferably uses a novel tertiary alcohol compound useful as a monomer for preparing a photoresist material having excellent transparency and affinity with a substrate in photolithography using a wavelength of 300 nm or less, particularly preferably ArF excimer laser light as a light source. To provide. 즉, 본 발명은 하기 화학식 1로 표시되는 3차 알콜 화합물을 제공한다. That is, the present invention provides a tertiary alcohol compound represented by the following formula (1). 식 중, R 1 , R 2 는 각각 독립적으로 탄소수 1 내지 10의 직쇄상, 분지상 또는 환상의 알킬기를 나타내고, 구성 탄소 원자 상의 수소 원자 중 일부 또는 전부가 할로겐 원자로 치환될 수도 있으며, 또한 R 1 , R 2 는 서로 결합하여 지방족 탄화수소환을 형성할 수도 있고, Z는 탄소수 2 내지 10의 직쇄상, 분지상 또는 환상의 2가의 유기기를 나타내며, k는 0 또는 1이다. In the formula, each of R 1 and R 2 independently represents a linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, and some or all of the hydrogen atoms on the constituent carbon atoms may be substituted with halogen atoms, and R 1 And R 2 may be bonded to each other to form an aliphatic hydrocarbon ring, Z represents a linear, branched or cyclic divalent organic group having 2 to 10 carbon atoms, and k is 0 or 1. 3차 알콜, 지환 구조 Tertiary alcohol, alicyclic structure

Synthesis method of aniline compound

本发明提供一种苯胺类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化硝基苯类化合物进行加氢还原反应；其中，所述碳包覆镍的纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氧的石墨化碳层，所述内核为镍纳米颗粒，所述纳米复合材料为具有至少一个介孔分布峰的介孔材料。该方法采用具有核壳结构的碳包覆镍的纳米复合材料为催化剂，其丰富的介孔结构，有利于催化反应的传质，用于硝基苯加氢还原合成苯胺，具有优异的活性、选择性及安全性。

Synthesis method of aminophenol compound

本发明提供一种氨基苯酚类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化硝基苯酚类化合物进行加氢还原反应；其中，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氮和氧的石墨化碳层，所述内核为镍纳米颗粒，其中所述纳米复合材料为具有至少一个介孔分布峰的介孔材料。该方法采用含核壳结构的碳包覆镍的纳米复合材料为催化剂，其丰富的介孔结构，有利于催化反应的传质，用于硝基苯酚类化合物加氢还原合成氨基苯酚类化合物，具有优异的活性、选择性及安全性。

A kind of synthetic method of naphthene-based compounds

本发明提供一种环烷烃类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化芳烃类化合物进行加氢还原反应；其中，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氮和氧的石墨化碳层，所述内核为镍纳米颗粒，其中所述纳米复合材料为具有至少一个介孔分布峰的介孔材料。该方法采用含核壳结构的碳包覆镍的纳米复合材料为催化剂，其丰富的介孔结构，有利于催化反应的传质，用于芳烃类化合物加氢还原合成环烷烃类化合物，具有优异的活性、选择性及安全性。

Method for preparing heterocyclideneacetamide derivatives

본 발명에 의해, 식 (I)로 표시되는 화합물 및 식 (I)의 제조 중간체인 식 (B)로 표시되는 화합물 또는 그의 염의 신규 제조 방법 등이 제공된다.

Monomer For Hardmask Composition, Hardmask Composition Including Monomer, And Method Of Forming Patterns By Using Hardmask Composition

本发明公开了一种由以下化学式1表示的用于硬掩膜组合物的单体、包括该单体的硬掩膜组合物、以及使用该硬掩膜组合物形成图案的方法。在以下化学式1中，A、A'、A″、L、L'、X、X'、m、和n与在具体实施方式中的定义相同。[化学式1]

METHOD FOR SYNTHESIS OF CYCLOGHEXENONES AND THEIR APPLICATION IN PERFUMES

1. Способ получения соединения формулы (I):,где - R1 представляет собой метил или этил;- R2 независимо представляет собой атом водорода или С1-С5-алкил или С2-С5-алкенил;- R3 представляет собой алкил или алкенил, необязательно замещенный арилом, или R3 представляет собой циклический алкил или циклический алкенил, необязательно замещенный одним или несколькими С1-С6-алкилами, при условии, что R3 содержит суммарно от 3 до 10 атомов углерода;- Z представляет собой С(О) или CR4(OR5), где:- R4 представляет собой атом водорода или С1-С8-алкил или С2-С8-алкенил;- R5 представляет собой атом водорода или С1-С8 алкил или алканоил или С2-С8алкенил или алкеноил;с учетом того, что двойная связь в цикле присутствует или отсутствует, и что, когда она присутствует, она находится:- или в положении 2-3, и R2 отсутствует в положении 2;- или в положении 3-4, и R2 присутствует в положении 2 и имеет определенные ранее значения;отличающийся тем, что в указанный способ включает следующие стадии:i) реакцию α-метиленальдегида в присутствии основания с симметричным кетоном с получением соединения формулы (Ia):,где R1 и R3 имеют определенные ранее значения, R2 представляет собой атом водорода, и в положении 2-3 или 3-4 цикла имеется двойная связь, причем после этой реакции необязательно следуют стадии ii), и/или iii), и/или iv);ii) реакцию моно- или бис-алкилирования для получения соединения формулы (1а), в которой R2 представляет собой С1-С5-алкил или С2-С5-алкенил;iii) конверсии функциональной группы Z=C(O) соединения, полученного на предыдущей стадии, в функциональную группу Z=CR4(OR5), в которой R4 и R5 имеют значения, определенные ранее;iv) восстановления двойной связи, находящейся в положении 2-3 или 3-4 в цикле соединения, полученного на предыдущей стадии, причем стадия iv) может быть осуществлена после РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 29/20 (13) 2015 116 505 A (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: ...

A kind of synthetic method of aminobenzoic ethers compound

本发明提供一种氨基苯甲醚类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化硝基苯甲醚类化合物进行加氢还原反应；其中，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氧的石墨化碳层，所述内核为镍纳米颗粒，所述纳米复合材料的酸洗损失率≤60％。该方法采用含核壳结构的碳包覆镍的纳米复合材料为催化剂，产生了良好的催化效果，并有利于在更苛刻的条件下发挥作用，用于硝基苯甲醚类化合物加氢还原合成氨基苯甲醚类化合物，具有优异的活性、选择性及安全性。

Process for crystallizing adduct of bisphenol A with phenol

A process for crystallizing the adduct of bisphenol A with phenol from a phenol solution in the presence of water comprises controlling the concentration of bisphenol A in said solution by removing portion of the phenol from said solution or adding phenol to said solution according to feedback control based on the measurement of solution density to obtain an adjusted solution, and feeding the adjusted solution to the crystallizer in which its inside wall is kept at a temperature higher than that of the adjusted solution, provided the temperature difference being smaller than 5° C. The crystallized adduct has a uniform particle size and a high purity.

Carbon coating cobalt nanocomposite and preparation method thereof

提供一种制备碳包覆钴纳米复合材料的方法，包括如下步骤：S1，由柠檬酸配位钴和乙二胺四乙酸配位钴中的一种或多种与六亚甲基四胺、尿素、二氰二胺和三聚氰胺中的一种或多种的混合形成前驱体；S2，在惰性保护气氛或还原气氛下将所述前驱体高温热解。本发明还提供该方法制备的碳包覆钴纳米复合材料。本发明通过利用配位的柠檬酸和乙二胺四乙酸与外加的六亚甲基四胺、尿素、二氰二胺和三聚氰胺中的一种或多种作为高温热解过程的碳、氮源及还原剂，热解过程中无需再通入H 2 、CH 4 、C 2 H 4 等可燃性气体。通过本发明制备方法形成的碳包覆钴纳米复合材料结构完整、分散性好、尺寸均一，并且经过酸洗处理后，其Co含量仍≥20％。此材料在电催化、吸波材料、润滑油添加剂、精细化工等领域有着广阔的应用前景。

Novel trimethylcyclododecatriene derivatives, use thereof and perfumed products containing said derivatives

FIELD: chemistry. SUBSTANCE: invention relates to mixtures of fragrant compounds selected from a mixture of compounds (5a-d), (6a-d), (6a'-6d'), (7a-d) and (7a'-7d'), to a method of preparing said mixtures, to fragrant, perfumed and cosmetic compositions, as well as to household chemicals based on said compounds and to use of said mixtures or fragrant compositions based on said compounds as a fragrant agent, an agent which masks or neutralises smell. (5a-d), (6a-d) and (7a-d), where R denotes a methyl group, (6a'-6d') and (7a'-7d'), where R denotes an ethyl group. EFFECT: preparing the mixtures of fragrant compounds. 16 cl, 1 dwg, 8 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 384 557 (13) C2 (51) МПК C07C C07C C07C C07C C07C C07C C11B ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, A61Q ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ C07C C07C (12) ОПИСАНИЕ 35/205 43/188 43/184 29/143 41/16 41/20 9/00 13/00 49/607 45/00 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (30) Конвенционный приоритет: 19.01.2005 FR 0500550 (73) Патентообладатель(и): В. МАН ФИС (FR) (43) Дата публикации заявки: 27.02.2009 2 3 8 4 5 5 7 (45) Опубликовано: 20.03.2010 Бюл. № 8 2 3 8 4 5 5 7 R U (85) Дата перевода заявки PCT на национальную фазу: 20.08.2007 (86) Заявка PCT: FR 2006/000081 (13.01.2006) (87) Публикация PCT: WO 2006/077306 (27.07.2006) Адрес для переписки: 103735, Москва, ул. Ильинка, 5/2, ООО "Союзпатент", пат.пов. А.Ю.Соболеву (54) НОВЫЕ ПРОИЗВОДНЫЕ ТРИМЕТИЛЦИКЛОДОДЕКАТРИЕНА, ИХ ПРИМЕНЕНИЕ И СОДЕРЖАЩИЕ ИХ ПАРФЮМЕРНЫЕ ПРОДУКТЫ композициям, а также продукту бытовой химии на их основе и к применению данных смесей или душистой композиции на их основе в качестве душистого агента, агента, маскирующего или нейтрализующего запах. Ñòð.: 1 ru C 2 C 2 (56) Список документов, цитированных в отчете о поиске: US 3723478 A, 27.03.1973. FR 1528158 A, 07.06.1968. NL 8700469 A, 16.09.1988. SU 1657483 A1, 23.06 ...

Tobacco-derived components and materials

The invention provides a method of extracting and isolating certain compounds from tobacco. The resulting isolate can include more than 90% by weight of a given compound and can be used as a flavor component for tobacco material used in smoking articles and smokeless tobacco compositions. Exemplary compounds that may be present in the isolate according to the invention include, but are not limited to, solanone, neophytadiene, megastigmatrienone, β-damascenone, norsolanadione, cis-abienol, α-cembratrienediol, β-cembratrienediol, sucrose esters, and lutein.

Method for synthesizing cyclohexenons and their use in perfumery

FIELD: chemistry.SUBSTANCE: invention relates to a process for preparing cyclohexenones and cyclohexenols having pleasant odors and special aftereffect properties, to new cyclohexenones and cyclohexenols, to a flavoring composition and to the use of cyclohexenones and cyclohexenols as flavoring agents.EFFECT: invention can be used in the manufacture of cosmetics, perfumes and detergents.13 cl, 1 tbl, 46 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C07C 29/20 (2006.01) C07C 29/143 (2006.01) C07C 41/01 (2006.01) C07C 45/62 (2006.01) C07C 45/68 (2006.01) C07C 67/08 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА C07C 35/18 (2006.01) ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ C07C 35/21 (2006.01) C07C 43/188 (2006.01) C07C 49/603 (2006.01) (12) (13) 2 663 619 C2 C07C 49/613 (2006.01) C07C 49/647 (2006.01) C07C 49/657 (2006.01) C07C 69/14 (2006.01) C07C 69/145 (2006.01) C07C 69/157 (2006.01) A61Q 13/00 (2006.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК (21)(22) Заявка: 2015116505, 24.09.2013 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): В. МАН ФИС (FR) Дата регистрации: 07.08.2018 (56) Список документов, цитированных в отчете о поиске: Ю.Гура и др. Исследование в Приоритет(ы): (30) Конвенционный приоритет: 05.10.2012 FR 1259524 (45) Опубликовано: 07.08.2018 Бюл. № 22 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.05.2015 R U 2 6 6 3 6 1 9 (86) Заявка PCT: FR 2013/052235 (24.09.2013) (87) Публикация заявки PCT: WO 2014/053744 (10.04.2014) Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" (54) СПОСОБ СИНТЕЗА ЦИКЛОГЕКСЕНОНОВ И ИХ ПРИМЕНЕНИЕ В ПАРФЮМЕРИИ (57) Реферат: Изобретение относится к способу получения и моющих средств, к новым циклогексенонам и циклогексенонов и циклогексенолов, обладающих циклогексенолам, к ароматизирующей приятными запахами и свойствами особого композиции и к применению циклогексенонов и последействия, которые могут быть использованы циклогексенолов в качестве ...

Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, either or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents

The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I: wherein wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R 1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR 1 , —N(R 1 ) 2 , R 1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR 1 , —N(R 1 ) 2 and —N(R 5 )SO 2 R 6 , wherein R 5 represents hydrogen or CH 2 OR 6 and R 6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is ═O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.

Prostaglandins and the preparation thereof

1324737 Medicines comprising prostaglandins UPJOHN CO 8 Oct 1971 [2 Nov 1970 29 July 1971] 47017/71 Heading ASB [Also in Divisions C2 and C3] Pharmaceutical compositions, suitable for oral, rectal, parenteral or topical administration contain prostaglandin derivatives of the formulae or mirror images thereof or racemic compounds thereof, wherein E is CH 2 CHR 4 or trans-CH=CR 4 ; R 1 is H, C 1-8 alkyl, C 3-10 cycloalkyl, C 7-12 aralkyl, phenyl optionally substituted with 1 to 3 chlorine atoms or C 1-4 alkyl radicals, or ethyl substituted in the beta position with 3 chlorine atoms, 2 or 3 bromine atoms or 1, 2 or 3 iodine atoms; wherein R 2 , R 3 and R 4 are H or C 1-4 alkyl; CtH 2 t is a valence bond or C 1-10 alkylene optionally substituted with 1 or 2 fluorine atoms, with 1 to 7 carbon atoms between CR 3 OH and the benzene ring; T is C 1-4 alkyl, F, Cl, CF 3 or OR 9 , wherein R 9 is H, C 1-4 alkyl or 2-tetra-hydropyranyl; s is 0 to 3, with the proviso that not more than 2 T's are other than alkyl and when 2 or 3 T's are present as substituents they are the same or different; V is C 3-12 alkylene optionally substituted with 1 to 4 fluorine atoms, with 3 to 7 carbon atoms between CHR 2 and COOR 1 with the proviso that when 3 or 4 fluorine atoms are present, they are all substituents of the carbon atoms alpha and beta to COOR 1 , cis or trans -CH=CHA or C#CA, wherein A is C 1-10 alklene optionally substituted with 1 to 4 fluorine atoms with 1 to 5 carbon atoms between =CH- or #C- and COOR 1 , with the proviso that when 3 or 4 fluorine atoms are present, they are all substituents of the carbon atoms alpha and beta to COOR 1 , with the further proviso that when E is CH 2 CHR 2 , U is C 3-12 alkylene as defined above; and - indicates the attachment of the group to the ring is alpha or beta, or the pharmacologically acceptable salts thereof when R 1 is H, or C 1-8 alkanoates thereof, together with pharmaceutically acceptable carriers. The compound possess similar ...

Phenyl-substituted prostaglandin-f type analogs

This invention is a group of phenyl-substituted PGE-type, PGF-type, PGA-type and PGB-type compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents

The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives, substituted in the 1-position with halo, methyl, hydroxyl, nitro, amino, amido, azido, oxime, cyano, thiol, either or thioether groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) derivatives of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) derivatives of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.

Novel method for isomerisation of condensed bicyclic structures and obtaining vitamin d analogues containing said structures

FIELD: chemistry. SUBSTANCE: invention relates to a method of producing a cis-condensed bicyclic derivative of formula (II) from a corresponding trans-condensed bicyclic derivative of formula (I), which includes a step of reacting said trans-condensed bicyclic derivative with a hydride base of formula M-H, where M is an atom of group IA. In general formula (I) and (II) R 1 is H or a C 1 -C 6 alkyl group; R 2 is H or D; where D is a deuterium atom; R 3 is C 1 -C 20 alkyl, optionally containing one or more double or triple bonds, and/or optionally containing one or more heteroatoms selected from O, N, S, Si; m is an integer selected from 0, 1, 2, 3; n is an integer selected from 0, 1 or 2; when they are present, each R i and R j , which are identical or different, respectively denote 1 to m or 1 to n groups, identical or different, independently selected from a halogen atom, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, OR, NRR', CN, NO 2 , perhalogeno (C 1 -C 6 )alkyl, COR, COOR, CONRR', alkylaryl, alkenylaryl, where R, R', identical or different, are selected from H, alkyl and aryl. EFFECT: providing a method of producing a cis-condensed bicyclic derivative of formula (II). 12 cl, 6 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 560 184 C2 (51) МПК C07C 49/403 (2006.01) C07C 401/00 (2006.01) A61K 31/59 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011102734/04, 25.01.2011 (24) Дата начала отсчета срока действия патента: 25.01.2011 Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): МУТУ Жан-Люк (FR), МУТОН Флоран (FR), ПЕЛЛЕГРИНО Жиль (FR), ЛАФЭ Жан (FR) (43) Дата публикации заявки: 27.07.2012 Бюл. № 21 R U (73) Патентообладатель(и): ИБРИЖЕНИКС СА (FR) 26.01.2010 EP 10305088.6 (45) Опубликовано: 20.08.2015 Бюл. № 23 2 5 6 0 1 8 4 R U (54) НОВЫЙ СПОСОБ ИЗОМЕРИЗАЦИИ КОНДЕНСИРОВАННЫХ БИЦИКЛИЧЕСКИХ СТРУКТУР И ПОЛУЧЕНИЕ АНАЛОГОВ ВИТАМИНА D, СОДЕРЖАЩИХ ЭТИ СТРУКТУРЫ (57) Реферат: Изобретение ...

Method for preparing 2-cyclohexyl cyclohexanol

화학식 (I)의 사이클로헥사논 이량체를 촉매를 함유하는 반응기에서 150 내지 250 ℃ 범위의 온도에서 수소 가스로 수소화하여 2-사이클로헥실 사이클로헥산올을 제조하는 단계를 포함하며 여기서 수소 가스 대 오일의 몰비는 1 내지 25의 범위인, 2-사이클로헥실 사이클로헥산올의 제조 방법이 제공된다. 이 방법은 고수율 특성의 이점을 가지며 대량 생산이 가능하여 산업상 이용 가치를 향상시킨다. hydrogenating a cyclohexanone dimer of formula (I) with hydrogen gas at a temperature ranging from 150 to 250° C. in a reactor containing a catalyst to produce 2-cyclohexyl cyclohexanol, wherein hydrogen gas to oil A process for the preparation of 2-cyclohexyl cyclohexanol is provided, wherein the molar ratio ranges from 1 to 25. This method has the advantage of high-yield characteristics and can be mass-produced, thereby improving the value of industrial use.

Carbon-coated transition metal nanocomposite and preparation method and application thereof

提供一种制备碳包覆过渡金属纳米复合材料的方法，包括如下步骤：S1，将包含过渡金属盐、多元有机羧酸和含氮化合物的混合物与溶剂混合，形成均相溶液；S2，除去所述均相溶液中溶剂，从而形成前驱体；及S3，在惰性保护气氛或还原气氛下，将所述前驱体高温热解。还提供由该方法制备的碳包覆过渡金属纳米复合材料及该材料的应用。本发明提供的方法更加简单高效，高温热解前驱体直接由过渡金属盐与多元有机羧酸在溶剂中均匀混合而得，前驱体过渡金属的原子利用率可达100％，克服了现有技术制备金属有机骨架结构前驱体需要使用高温高压反应釜自组装、大量浪费有机溶剂、提纯步骤繁琐等缺点。本发明的复合材料中，过渡金属纳米粒子被石墨化碳层包覆的严密程度更高，能在更苛刻的条件下使用。

SHIP1 MODULATORS AND RELATED WAYS

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2015 143 675 A (51) МПК C07C 215/42 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2015143675, 27.02.2014 (71) Заявитель(и): ЭКУИНОКС ФАРМАСЬЮТИКАЛЗ (КЭНЭДА) ИНК. (CA) Приоритет(ы): (30) Конвенционный приоритет: 14.03.2013 US 61/785,860 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 14.10.2015 (86) Заявка PCT: (87) Публикация заявки PCT: WO 2014/143561 (18.09.2014) (54) SHIP1 МОДУЛЯТОРЫ И ОТНОСЯЩИЕСЯ К НИМ СПОСОБЫ (57) Формула изобретения 1. Соединение формулы (I): A 2 0 1 5 1 4 3 6 7 5 A Адрес для переписки: 129090, Москва, ул. Б. Спасская, 25, стр. 3, ООО "Юридическая фирма Городисский и Партнеры" каждый C1, C4, C11 и C12 независимо замещен двумя водородами; C9 замещен одним водородом; R U 2 0 1 5 1 4 3 6 7 5 US 2014/019125 (27.02.2014) R U (43) Дата публикации заявки: 27.04.2017 Бюл. № 12 (72) Автор(ы): МАККЕНЗИ Ллойд Ф. (CA), ХАРВИГ Кертис (CA), БОГУЦКИ Дэвид (CA), РЭЙМОНД Джеффри Р. (CA), ПЕТТИГРЮ Джереми Д. (CA) C14 замещен одним водородом, когда R5 не представляет собой простую связь с C14; C15 замещен двумя водородами; R1 представляет собой -R8-OR9 или -R8-N(R9)2; R2 представляет собой -R8-OR9, -R8-CN, -R8-C(O)OR9, -R8-C(O)N(R9)2, -R8-N(R9)2, Стр.: 1 -R8-N(R9)C(O)R9, необязательно замещенный гетероциклоалкил или необязательно замещенный гетероарилалкил; R4a представляет собой водород или алкил, R4b представляет собой простую связь с атомом углерода, с которым соединен R7, и R3 представляет собой -CH2NH2 или -CH2N (H)C(O)(CH2)3CH3; R5 представляет собой алкил, или R5 представляет собой простую связь с C14; R6 представляет собой водород; R7 представляет собой водород или -R8-OR9; каждый R8 независимо представляет собой простую связь или нормальную или разветвленную алкиленовую цепь; и R U R4a представляет собой водород или алкил, R4b представляет собой простую связь с атомом углерода, с которым соединен R7, и R3 представляет собой -CH2NH2 или - ...

A kind of nanocomposite of carbon coating transition metal and application

本发明提供一种碳包覆过渡金属的纳米复合材料及应用，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氧的石墨化碳层，内核为过渡金属纳米颗粒，其中，所述纳米复合材料的酸洗损失率≤10％。该纳米复合材料具有严密包覆的石墨化碳层，通过这种严密包覆的结构可以更好的保证内核过渡金属在制备和应用中损失率降低，从而更好的发挥复合材料的作用并保证了复合材料的安全性。本发明的碳包覆过渡金属的纳米复合材料制备方法简单，适用性广，作为催化剂催化效果佳，可用于各类加氢还原反应。

Derivatives of aromatic cyclic alkylethers

The present invention provides compounds of the formula: ##STR1## and the pharmaceutically acceptable salts thereof, wherein: R 1 and R 2 are each alkyl; n is an integer of from 1 to 4; x is oxygen or --(CH 2 ) m --; m is an integer of from 1 to 3; y is oxygen or sulfur; and p is an integer of from 1 to 4. These compounds are inhibitors of COX-I and/or COX-II, and are useful for the treatment of inflammation-associated disorders. The present invention also provides pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for treating inflammation-associated disorders in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.

Synthesis method of halogenated aniline

本发明提供一种卤代苯胺的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化卤代硝基苯进行加氢还原反应；其中，所述纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氮和氧的石墨化碳层，所述内核为镍纳米颗粒，其中所述纳米复合材料为具有至少一个介孔分布峰的介孔材料。该方法采用碳包覆镍的纳米复合材料为催化剂，其丰富的介孔结构，有利于催化反应的传质，其包覆严密的金属纳米粒子，有利于在更苛刻的条件下发挥作用，用于卤代硝基苯加氢还原合成卤代苯胺，具有优异的活性、选择性及安全性，并能有效改善反应过程中的脱卤问题。

METHOD FOR PRODUCING DI (MET) ISOSORBIDE ACRYLATE

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2017 133 283 A (51) МПК C09J 4/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2017133283, 24.02.2016 (71) Заявитель(и): БАСФ СЕ (DE) Приоритет(ы): (30) Конвенционный приоритет: 26.02.2015 US 62/120,922 09 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 26.09.2017 EP 2016/053858 (24.02.2016) (87) Публикация заявки PCT: A WO 2016/135191 (01.09.2016) Адрес для переписки: 105064, Москва, а/я 88, ООО "Патентные поверенные Квашнин, Сапельников и партнеры" R U (57) Формула изобретения 1. Способ получения ди(мет)акрилата изосорбида переэтерификацией алкил(мет) акрилата изосорбидом, который включает стадии: (i) взаимодействие алкил(мет)акрилата с изосорбидом в присутствии содержащего титан (IV) или цирконий (IV) катализатора и стабилизатора, а также в присутствии азеотропообразующего агента, образующего со связанным в алкил(мет)акрилате спиртом азеотропную смесь, (ii) непрерывную отгонку азеотропной смеси из азеотропообразующего агента и спирта, причем стадии (i) и (ii) реализуют одновременно, пока не достигнут в основном полного превращения изосорбида, (iii) добавление воды к полученной на стадиях (i) и (ii) смеси продуктов, содержащей ди(мет)акрилат изосорбида, и отделение продукта гидролиза содержащего титан (IV) или цирконий (IV) катализатора, (iv) отгонку непревращенного алкил(мет)акрилата и азеотропообразующего агента из смеси продуктов, (v) отгонку воды из смеси продуктов, причем стадию (iv) можно осуществлять также перед стадией (iii), а стадии (iv) и (v) можно осуществлять также на единой стадии дистилляции. Стр.: 1 A 2 0 1 7 1 3 3 2 8 3 (54) СПОСОБ ПОЛУЧЕНИЯ ДИ(МЕТ)АКРИЛАТА ИЗОСОРБИДА 2 0 1 7 1 3 3 2 8 3 (86) Заявка PCT: R U (43) Дата публикации заявки: 27.03.2019 Бюл. № (72) Автор(ы): МИССКЕ Андреа (DE), ФЛЯЙШХАКЕР Фридерике (DE), ФЛЕККЕНШТАЙН Кристоф (DE), КАЛЛЕР Мартин (DE), НАИР Ритеш (DE), ШТЕНГЕЛЬ Ульрик (DE), БЛАНХОТ Матие (DE) A 2 0 1 7 1 3 ...

A process for isolation purification and recrystallization of lutein from saponified marigold oleoresin and uses thereof

순수 루테인 바람직하게는, 금잔화 함유수지로부터 화학적 불순물 및 카로티노이드가 함유되지 않은 순수 유리상태의 루테인을 분리, 정제 및 재결정하는 방법으로서, 순수한 형태의 루테인은 분석표준물질로 쓸 수도 있으며, 산화방지제로서의 영양보충제, 식품 색 첨가제, 노화성 반점 변질 및 백내장과 같은 눈병, 심장병, 암을 방지하는 제제로도 사용할 수 있다. Pure Lutein A method for separating, purifying and recrystallizing pure free lutein free of chemical impurities and carotenoids from marigold containing resins.Pure lutein may also be used as analytical standard, and as nutritional antioxidant It can also be used as a supplement to prevent eye disease, heart disease, cancer such as supplements, food color additives, aging spot deterioration and cataracts.

Novel biphenyl derivative compound and use thereof

본 발명은, 신규 바이페닐 유도체 화합물, 또는 이의 약학적으로 허용가능한 염을 제공한다. 본 발명에 따른 바이페닐 유도체 화합물, 또는 이의 약학적으로 허용가능한 염은 Nm23-H1/NDPK 활성 증진 물질로 암의 전이 및 성장을 억제할 수 있어 암의 예방, 개선 및 치료뿐만 아니라 암전이 억제에 우수한 효과를 나타낸다.

NEW DERIVATIVES OF TRIMETHYLCYCLODODECATRIENE, THEIR APPLICATION AND THEIR PERFUMERY PRODUCTS CONTAINING THEM

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2007 131 287 (13) A (51) ÌÏÊ C07C 49/607 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2007131287/04, 13.01.2006 (71) Çà âèòåëü(è): Â. ÌÀÍ ÔÈÑ (FR) (30) Êîíâåíöèîííûé ïðèîðèòåò: 19.01.2005 FR 0500550 (43) Äàòà ïóáëèêàöèè çà âêè: 27.02.2009 Áþë. ¹ 6 (87) Ïóáëèêàöè PCT: WO 2006/077306 (27.07.2006) Àäðåñ äë ïåðåïèñêè: 103735, Ìîñêâà, óë. Èëüèíêà, 5/2, ÎÎÎ "Ñîþçïàòåíò", ïàò.ïîâ. À.Þ.Ñîáîëåâó (54) ÍÎÂÛÅ ÏÐÎÈÇÂÎÄÍÛÅ ÒÐÈÌÅÒÈËÖÈÊËÎÄÎÄÅÊÀÒÐÈÅÍÀ, ÈÕ ÏÐÈÌÅÍÅÍÈÅ È R U (57) Ôîðìóëà èçîáðåòåíè 1. Ñîåäèíåíèå ïðèâåäåííîé íèæå îáùåé ôîðìóëû (I) A 2 0 0 7 1 3 1 2 8 7 A ÑÎÄÅÐÆÀÙÈÅ ÈÕ ÏÀÐÔÞÌÅÐÍÛÅ ÏÐÎÄÓÊÒÛ â êîòîðîé A) a) êàæäûé èç R4, R5 è R7 îáîçíà÷àåò àòîì âîäîðîäà, à êàæäûé èç R3, R6 è R8 îáîçíà÷àåò ìåòàëüíûé ðàäèêàë, èëè b) êàæäûé èç R4, R6 è R7 îáîçíà÷àåò àòîì âîäîðîäà, à êàæäûé èç R3, R5 è R8 îáîçíà÷àåò ìåòàëüíûé ðàäèêàë, èëè c) êàæäûé èç R3, R6 è R7 îáîçíà÷àåò àòîì âîäîðîäà, à êàæäûé èç R4, R5 è R8 îáîçíà÷àåò ìåòàëüíûé ðàäèêàë, è îáîçíà÷åííûå ïóíêòèðîì ñâ çè ïðèñóòñòâóþò è îáîçíà÷àþò öèñ- èëè òðàíñ-äâîéíûå ñâ çè, a R1 îáîçíà÷àåò àòîì âîäîðîäà è R; îáîçíà÷àåò ãðóïïó -ÎÍ, -ÎÑÍ3 èëè -OC2H5, èëè Ñòðàíèöà: 1 RU 2 0 0 7 1 3 1 2 8 7 (86) Çà âêà PCT: FR 2006/000081 (13.01.2006) R U (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 20.08.2007 (72) Àâòîð(û): ÌÀÍ Æàí (FR), ØÀÍÎ Æàí-Æàê (FR), ØÐÅÄÅÐ Ìàðòèí (GB) îáîçíà÷åííûå ïóíêòèðîì ñâ çè îòñóòñòâóþò, à R1 îáîçíà÷àåò àòîì âîäîðîäà è R2 îáîçíà÷àåò ãðóïïó -ÎÑÍ3 èëè -ÎÑ2Í5, èëè B) êàæäûé èç R1, R4 è R6 îáîçíà÷àåò àòîì âîäîðîäà, à êàæäûé èç R2, R3 è R5 îáîçíà÷àåò ìåòàëüíûé ðàäèêàë è îáîçíà÷åííûå ïóíêòèðîì ñâ çè ïðèñóòñòâóþò è îáîçíà÷àþò öèñ- èëè òðàíñ-äâîéíûå ñâ çè, à R7 îáîçíà÷àåò àòîì âîäîðîäà è R8 îáîçíà÷àåò ãðóïïó -ÎÍ, -ÎÑÍ3 èëè -OC2H5, èëè îáîçíà÷åííûå ïóíêòèðîì ñâ çè îòñóòñòâóþò, à R7 îáîçíà÷àåò àòîì âîäîðîäà è R8 îáîçíà÷àåò ãðóïïó -ÎÑÍ3 èëè -ÎÑ2Í5, ïðè÷åì óêàçàííîå ñîåäèíåíèå âë åòñ ñïèðòîâûì ïðîèçâîäíûì èëè ...

A kind of synthetic method of cyclohexanol kind compound

本发明提供一种环己醇类化合物的合成方法，包括：以碳包覆镍的纳米复合材料为催化剂，在氢气气氛下催化苯酚类化合物进行加氢还原反应；其中，所述碳包覆镍的纳米复合材料含具有壳层和内核的核壳结构，所述壳层为掺杂氧的石墨化碳层，所述内核为镍纳米颗粒，所述纳米复合材料的酸洗损失率≤60％。该方法采用含核壳结构的碳包覆镍的纳米复合材料为催化剂，其丰富的介孔结构，有利于催化反应的传质，用于苯酚类化合物加氢还原合成环己醇类化合物，具有优异的活性、选择性及安全性。

Cycloalkane oxidation catalysts and method to produce alcohols and ketones

본 발명은 사이클로알칸을 산화시켜 상응하는 알코올 및 케톤을 포함하는 생성물 혼합물을 형성하는 방법에 관한 것이며, 상기 방법은 금속 트리플레이트 또는 금속 트리플미데이트 촉매의 촉매 유효량의 존재 하에서 사이클로알칸을 산화제와 접촉시키는 단계를 포함한다. The present invention relates to a method for oxidizing a cycloalkane to form a product mixture comprising the corresponding alcohol and ketone, the method comprising contacting a cycloalkane with an oxidizing agent in the presence of a catalytically effective amount of a metal triflate or metal trifamide catalyst. It includes the step of making.

Process for producing alcohol or amine

Disclosed herein is a process for producing an alcohol or an amine by reducing a compound having a formyl, keto, nitro, oxirane, ester, nitrile, amide or halogenated carboxyl group with an alkali metal boro-hydride in the presence of a compound having a hydroxyl group and ether linkage. According to the present invention, a functional group having a great steric hindrance can be reduced, and a corresponding alcohol or amine can efficiently be produced under very mild conditions on an industrial scale.

New incense-imparting agent

(57)【要約】 【課題】 長く持続する強いびゃくだん調のにおいを有 し、多数の天然および合成未加工香料材料と調和する新 規着香物質を提供する。 【解決手段】 【化１】 式中、Ｒ 1 からＲ 7 は独立してＨ、メチルあるいはエチ ルであり、Ｒ 8 ＋Ｒ 9 はメチレン（−ＣＨ 2 −）あるい は単結合を表わし、またはＲ 1 ＋Ｒ 2 は−（ＣＨ 2 ） n −（ｎは３あるいは４である）も形成することができ、 Ｒ 3 ＋Ｒ 5 あるいはＲ 5 ＋Ｒ 7 はメチレン、単結合ある いは２個の水素も表わすことができ、分子中に必ず少な くとも１個のシクロプロパン環が存在しなければなら ず、そして側鎖は飽和であることができ、またはα，β 位かβ，γ位に一つの二重結合を含むことができる、を 有する化合物。

METHOD OF OBTAINING 2-BUTYL-1-TERM

1344653 Alcohols and esters L GIVAUDAN & CIE SA 10 Nov 1971 [10 Nov 1970] 52176/71 Heading C2C [Also in Division A5] The invention comprises compounds of the formula where R<SP>1</SP> is H or methyl, R<SP>11</SP> is H or alkanoyl of 1-3 carbon atoms, R<SP>111</SP> is butyl, Z is -C#C-, -CH=CH- or -CH 2 -CH 2 - and n is 0-2. The compounds are prepared by .reacting together compounds of the formula and MZR<SP>1</SP> where M is an alkali metal or MgX where X is halogen, provided that M is an alkali metal only when Z is -C#C-, and alkanoylating or hydrogenating the product if desired.

Process for the preparation of tricyclodecane-dimethylols by hydroformylation of dicyclopentadiene over rhodium-containing catalysts and subsequent hydrogenation to give the corresponding diols

Tricyclodecane dimethanol compositions and uses thereof

提供一種三環癸烷二甲醇系組合物，其含有特定量之組分且能使由其所製得之產品具有改善的流動性及光學性質。

Process for the preparation of 3 (4), 7 (8) -dihydroxymethyl-bicyclo (4.3.0) nonane

Verfahren zur Herstellung von 3(4),7(8)-Dihydroxymethyl-bicyclo[4.3.0]nonan durch Hydroformylierung von Bicyclo[4.3.0]nona-3,7-dien mit nachfolgender Hydrierung, dadurch gekennzeichnet, dass man Bicyclo[4.3.0]nona-3,7-dien in homogener organischer Phase in Gegenwart von Triarylphosphine in komplexer Bindung enthaltenden Rhodiumverbindungen und überschüssigem Triarylphosphin bei Temperaturen von 70 bis 160°C und Drücken von 10 bis 30 MPa mit Synthesegas umsetzt, wobei man Rhodium in einer Konzentration von 10 bis 500 Gew.-ppm, bezogen auf das homogene Reaktionsgemisch einsetzt und wobei das molare Verhältnis von Rhodium zu Phosphor 1:10 bis 1:200 beträgt, und das so erhaltene 3(4),7(8)-Bisformyl-bicyclo[4.3.0]nonan anschließend zum 3(4),7(8)-Dihydroxymethyl-bicyclo[4.3.0]nonan hydriert. method for the preparation of 3 (4), 7 (8) -dihydroxymethyl-bicyclo [4.3.0] nonane by hydroformylation of bicyclo [4.3.0] nona-3,7-diene with subsequent hydrogenation, characterized in that bicyclo [4.3.0] nona-3,7-diene in homogeneous organic phase in the presence of triarylphosphines complexed rhodium compounds and excess triarylphosphine at temperatures of 70 to 160 ° C and pressing from 10 to 30 MPa with synthesis gas, where rhodium in a concentration of 10 to 500 ppm by weight, based on the homogeneous Reaction mixture is used and wherein the molar ratio of rhodium to phosphorus is 1:10 to 1: 200, and the thus obtained 3 (4), 7 (8) -bisformyl-bicyclo [4.3.0] nonane subsequently to Hydrogenated 3 (4), 7 (8) -dihydroxymethyl-bicyclo [4.3.0] nonane.

Patent RU2017133283A3

РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2017 133 283 A (51) МПК C09J 4/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2017133283, 24.02.2016 (71) Заявитель(и): БАСФ СЕ (DE) Приоритет(ы): (30) Конвенционный приоритет: 26.02.2015 US 62/120,922 09 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 26.09.2017 EP 2016/053858 (24.02.2016) (87) Публикация заявки PCT: A WO 2016/135191 (01.09.2016) Адрес для переписки: 105064, Москва, а/я 88, ООО "Патентные поверенные Квашнин, Сапельников и партнеры" R U (57) Формула изобретения 1. Способ получения ди(мет)акрилата изосорбида переэтерификацией алкил(мет) акрилата изосорбидом, который включает стадии: (i) взаимодействие алкил(мет)акрилата с изосорбидом в присутствии содержащего титан (IV) или цирконий (IV) катализатора и стабилизатора, а также в присутствии азеотропообразующего агента, образующего со связанным в алкил(мет)акрилате спиртом азеотропную смесь, (ii) непрерывную отгонку азеотропной смеси из азеотропообразующего агента и спирта, причем стадии (i) и (ii) реализуют одновременно, пока не достигнут в основном полного превращения изосорбида, (iii) добавление воды к полученной на стадиях (i) и (ii) смеси продуктов, содержащей ди(мет)акрилат изосорбида, и отделение продукта гидролиза содержащего титан (IV) или цирконий (IV) катализатора, (iv) отгонку непревращенного алкил(мет)акрилата и азеотропообразующего агента из смеси продуктов, (v) отгонку воды из смеси продуктов, причем стадию (iv) можно осуществлять также перед стадией (iii), а стадии (iv) и (v) можно осуществлять также на единой стадии дистилляции. Стр.: 1 A 2 0 1 7 1 3 3 2 8 3 (54) СПОСОБ ПОЛУЧЕНИЯ ДИ(МЕТ)АКРИЛАТА ИЗОСОРБИДА 2 0 1 7 1 3 3 2 8 3 (86) Заявка PCT: R U (43) Дата публикации заявки: 27.03.2019 Бюл. № (72) Автор(ы): МИССКЕ Андреа (DE), ФЛЯЙШХАКЕР Фридерике (DE), ФЛЕККЕНШТАЙН Кристоф (DE), КАЛЛЕР Мартин (DE), НАИР Ритеш (DE), ШТЕНГЕЛЬ Ульрик (DE), БЛАНХОТ Матие (DE) A 2 0 1 7 1 3 ...

Enzymatic resolution of endo-bicyclo(2.2.1)heptan-2-ol

A mammalian pancreatic lipase mediated transesterification method for the optical resolution of endo-norborneol.

Carbocyclic and heterocyclic hiv protease inhibitors

Compounds of formula (I) wherein R1 and R4 are OH, (CHR5)mCOR6, (CHR5)mCH(OH)R5 or R5; R2 and R3 are H, C1-8alkyl, Het, C3-10cycloalkyl, Het-C1-8alkyl, C2-8alkenyl, Het-C2-8alkenyl, C3-10cycloalkyl-C1-8alkyl or C3-10cycloalkyl-C2-8alkenyl; R5 is R2 or R2 mono- or di-substituted by G; R6 is H, OH, OR', R2, N(R')2, AA or NHC(=NR7)NHR''; R¿7? is H, CN, COR' or SO2R'; R' is H, C1-6alkyl, C3-10cycloalkyl or C1-8alkyl-C3-10cycloalkyl; R'' is R', COR', C(O)OR' or CON(R')2; G is OR', OC(O)R', OC(O)N(R')2, halogen, COR6, NR'-AA, NHCOR', SO2N(R')2, NHSO2N(R')2, NHC(=NR?7¿)NHR'', CF¿3? or N(R')2; AA is one or two amino acids; Z is CH2, CHOH, CHN(R')2, CHNHCOOR, S, SO, SO2, SONH, O, CHCH2OH, CHCO2H, C=O, NR'', N(O)R' or C=NHOR'; Q is CHOH, S, SO or SO2; m is 0, 1 or 2; n is 0 or 1; and pharmaceutically acceptable salts thereof, inhibit the HIV-1 protease and are useful in the treatment of AIDS.

Patent FR2112390B1

PROSTAGLANDIN ANALOGS

Patent FR2455018B1

Patent FR2361100B1

PROCESS FOR THE SYNTHESIS OF CYCLOHEXENONES AND THEIR USE IN PERFUMERY

Patent FR2267296B1

New compounds of 2, 2-dialkylcyclobutanone and of 2, 2-dialkylcyclobutanol and process for their preparation

ALLETHROLONE DERIVATIVES AND THEIR PREPARATION PROCESS

L'INVENTION A POUR OBJET LES COMPOSES DE FORMULE(I) (CF DESSIN DANS BOPI) DANS LAQUELLE, NOTAMMENT, R ET R REPRESENTENT DE L'HYDROGENE, UN ATOME D'HALOGENE, UN RADICAL ALCOYLE, UN GROUPEMENT CYANO ET R ET R REPRESENTENT DE L'HYDROGENE OU UN RADICAL ALCOYLE SATURE OU NON, LES COMPOSES DE FORMULE I POUVANT ETRE DE CONFIGURATION S, R OU RACEMIQUES. L'INVENTION A EGALEMENT POUR OBJET UN PROCEDE DE PREPARATION DES COMPOSES I PAR REACTION DE WITTIG A PARTIR DES COMPOSES DE FORMULEII): (CF DESSIN DANS BOPI) DANS LAQUELLE A REPRESENTE DE L'HYDROGENE, UN RESTE D'ACIDE CARBOXYLIQUE OU UN RESTE D'ETHER ET R ET R CONSERVENT LES SIGNIFICATIONS PRECITEES. LES COMPOSES (I) SERVENT A PREPARER DES ESTERS INSECTICIDES. THE OBJECT OF THE INVENTION IS THE COMPOUNDS OF FORMULA (I) (CF DRAWING IN BOPI) IN WHICH, IN PARTICULAR, R AND R REPRESENT HYDROGEN, A HALOGEN ATOM, A RADICAL ALCOYL, A CYANO AND R AND R GROUP REPRESENT HYDROGEN OR A SATURATED OR UNSATURATED ALCOHYL RADICAL, THE COMPOUNDS OF FORMULA I MAY BE OF S, R OR RACEMIC CONFIGURATION. THE SUBJECT OF THE INVENTION ALSO IS A PROCESS FOR THE PREPARATION OF COMPOUNDS I BY REACTION OF WITTIG FROM COMPOUNDS OF FORMULA II): (CF DRAWING IN BOPI) IN WHICH REPRESENTS HYDROGEN, A RESIDENCE OF CARBOXYLIC ACID OR A REMAIN DE ETHER AND R AND R KEEP THE FOREGOING MEANINGS. COMPOUNDS (I) ARE USED TO PREPARE INSECTICIDE ESTERS.

NEW ODORING SUBSTANCES WITH MUSK ODOR AND PROCESS FOR THEIR PREPARATION

L'invention concerne de nouveaux 1-acyl ou 1-hydroxyméthyl-cyclododécanes ou cyclododécènes ainsi qu'un procédé pour leur fabrication. Selon l'invention les cyclododécanes et les cyclododécènes sont de formule générale : The invention relates to novel 1-acyl or 1-hydroxymethyl-cyclododecanes or cyclododecenes and to a process for their manufacture. According to the invention, the cyclododecanes and the cyclododecenes are of general formula:

PROCESS FOR THE SYNTHESIS OF CYCLOHEXENONES AND THEIR USE IN PERFUMERY

La présente invention se rapporte à un procédé de synthèse de composés cyclohexènones et cyclohexènols présentant des fragrances et des propriétés de rémanence particulières, ledit procédé consistant en la condensation d'une cétone sur un α-méthylène-aldéhyde afin d'obtenir par une réaction domino, des composés de formule (I) suivante : The present invention relates to a process for the synthesis of cyclohexenone and cyclohexenols compounds having particular fragrances and remanence properties, said process consisting of the condensation of a ketone on an α-methylene-aldehyde to obtain by a domino reaction compounds of formula (I) below:

Anti-histamine and stimulant drug based on dibenzocycloheptane derivatives.

New compounds of 2, 2-dialkoyl-3- (1-alkenyl) cyclobutanes, process for their preparation and applications

Improvements to axial flow fluid machines

Patent FR2113740A5

1α-hydroxy vitamin D4 and novel intermediates and analogues

Disclosed is 1α,24-dihydroxy vitamin D 4 having the following structure: ##STR1## and pharmaceutical compositions containing said compound. The compound and composition are useful in the treatment of abnormal calcium metabolism. Also Disclosed is a method for the preparation of 1α,24-dihydroxy vitamin D 4 .

Myrtenol synthesis - by isomerisation of beta-pinene epoxide

Myrtenol is prepd. by isomerisation of beta-pinene epoxide in presence of strongly basic reagent. Basic reagent is selected from organo-metallic cpds., Al, Na, K, Li alcoholates, Na or Li mono- or di-alkyl amides. Pref. epoxide is prepd. by oxidn. of beta-pinene in basic medium by oxygenated water in presence of organic nitrile. Simple synthesis is selective and gives high yield.

NOVEL TRIMETHYLCYCLODODECATRIENE DERIVATIVES, THEIR USE AND FRAGRANCE PRODUCTS CONTAINING SAME

Novel trimethylcyclododecatriene derivatives, use thereof, and perfumed products containing the same

The invention relates to a compound of general formula (I) wherein: A) a) R4, R5, and R7 each represent a hydrogen atom and R3, R6 and R8 each represent a methyl radical, or b) R4, R6, and R7 each represent a hydrogen atom and R3, R5 and R8 each represent a methyl radical, or c) R3, R6 and R7 each represent a hydrogen atom and R4, R5 and R8 each represent a methyl radical, and the dotted lines are present and represent cis-double bonds or trans-double bonds, and R1 represents a hydrogen atom and R2 represents an OH, OCH3 or OC2H5 group, or the dotted lines are absent and R1 represents a hydrogen atom and R2 represents an OCH3 group or an OC2H5 group; or B) R1, R4, and R6 each represent a hydrogen atom and R2, R3 and R5 each represent a methyl radical, and the dotted lines are present and represent cis-double bonds or trans-double bonds, and R7 represents a hydrogen atom and R8 represents an OH, OCH3 or OC2H5 bond, or the dotted lines are absent and R7 represents a hydrogen atom and R8 represents an OCH3 group or an OC2H5 group. The inventive compound is an alcoholic derivative or an ether derivative. The invention also relates to the use of at least one compound of formula (I) as an odorant agent.

Cyclic olefin hydration process

Patent FR1572146A

Antiinflammatory aralkyl hydrocarbons

Preparations contg. aralkyl-hydrocarbons Ar-R are pharmaceutical and veterinary antiinflammatories free from gastric side effects. Ar = 3- or 4-C6H5OC6 H5, 4-C6H5O-3-Me-(or 3-MeO)-C6H5, 4-C6H5SC6H5, 4-C6H11-C6H5 (or -3-ClC6H5), 4-cyclooctyl-(or 4-(1-cyclooctenyl))-C6H5, 4-isoC4H9- or -iso-C3H7-C6H5, 4-t-C4H9-C6H5 or 5-indanyl, R = iso-propyl or isopropenyl, iso- or n-butyl, if R = iso butyl, Ar = phenoxyphenyl, and if R = n-butyl, Ar = 4-biphenylyl. Prepn. is e.g. from aralkyl-ketones with Grignard reagents and subsequent catalytic hydrogenation.

Odorant compositions contg. polycyclic aliphatic cpds. - contg. a cyclobutane ring

New odorant compsns. contain a wholesome-smelling amt. of a cpd. of formula (I), (II) and/or (III). In the formulae, n is 0 or 1; A,aB and C are H, or 1-3C alkyl, provided that >=1 is other than H when n is 0; D and E are H, 1-6C alkyl (provided that the sum of C-atoms in D and E does not exceed 6), 1-5C alkoxy, or a gp. -OCOR in which R is 1-6C alkyl or aryl, provided that when one of D and E is alkoxy or -OCOR then the other of D and E is H; m is 1-8; F and G are H or 1-3C alkyl; and X is a gp. in which p is 0, 1 or 2 and I and J are H or CH3, provided that m is >2 when p is 0; provided that the total number of C- and O-atoms in the cpds. is not >23. The compsns. also contain a carrier material usual in odorant compsns. Cpds. of formula (VI) (which fall within formula (II)) are claimed as new. In formula (VI), m is 0-8; and F and G are H or 1-3C alkyl. (I)-(I)I) have very pleasant, strong and long-lasting odours and can be used for the prodn. and formulation of odorant compsns. such as perfumes and perfumed prods., e.g. cosmetic prepns., washing agents and fine soaps. A perfume compsn. in an example has a pleasant woody odour. It contains 7 wt. pts. coumarin, 1 pt. vanillin, 2 pts. cedrenyl acetate, 3 pts. cedarwood oil, 0.5 pts. cinnamon leaf oil, 1 pt. diphenylmethane, 1 pt. eugenol, 1745 pts. hydrogenated resin, ester, 20 pts. 5,5,7-trimethyltricyclo/6.4.0.02,7/dodecan-3-ene, 4 pts. isopropylquinols, 1 pt. linalool, 14 pts. olibanum extract, 1 pt. "Candela GD" (RTM), 6 pts. terpinyl acetate, 20 pts. phenylethyl alcohol and 1 pt. ethyl cinnamate.